Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00304148 · ClinicalTrials.gov registry record

SDCC - Prospective Cohort Study of Chronic Renal Insufficiency

A clinical trial of Renal Insufficiency, Chronic, sponsored by University of Pennsylvania.

Active
Registry status
5,499
Enrollment target
12
Study locations

NCT00304148 is a study of Renal Insufficiency, Chronic that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 5,499 participants, above the 257-participant average among 14 other Renal Insufficiency, Chronic trials with a reported enrollment target (2040% higher). The trial reports 12 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00304148, a study of Renal Insufficiency, Chronic, is active but no longer recruiting, sponsored by University of Pennsylvania.

ACTIVE NOT RECRUITING
Registry status
5,499 participants
Enrollment target
12
Study locations

Study Summary

Chronic kidney disease (CKD) is a silent epidemic affecting more than 37 million Americans. The burden of morbidity and mortality associated with CKD derives from its frequent progression to end-stage kidney disease (ESKD) and the disproportionate risk of cardiovascular disease (CVD) and associated complications. CKD is strongly and independently associated with CVD, even after adjustment for traditional CVD risk factors. This led to the hypothesis that other risk factors augment the rate of CVD in the setting of CKD. Hence, many patients with progressive renal disease succumb to fatal CVD events before they need renal replacement therapy. The National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) established the Chronic Renal Insufficiency Cohort (CRIC) Study in 2001 with the initial goal of elucidating the relationship between CKD and CVD. Since its inception, the CRIC Study has recruited and followed a racially and ethnically diverse cohort of over 5,000 participants with reduced kidney function from 13 clinical recruitment sites across the US. The original aim of CRIC was to establish a clinical research laboratory designed to (a) identify novel predictors of CKD progression, and (b) characterize the manifestations of CVD and identify its risk factors among individuals with CKD. The CRIC Study has examined a broad set of etiological factors (clinical, behavioral, and biomarker-associated) potentially responsible for both progressive CKD and CKD-related morbidities, especially those early in the course of CKD. Characterizing relationships between these risk factors and outcomes should facilitate identification of high-risk subgroups with CKD and guide enrollment into preventive treatment trials and application of preventive therapies. Over time, the scientific focus and the CRIC investigator network have broadened extensively through a highly successful ancillary studies program that has included more than 100 projects, most of which have been fu

Study Locations (12)

Ohio

  • University Hospitals of Cleveland - Cleveland
  • Metrohealth Medical Center - Cleveland
  • Cleveland Clinic Foundation - Cleveland

California

  • Kaiser Permanente of Northern California - Oakland
  • University of California - San Francisco

Maryland

  • University of Maryland Medical System - Baltimore
  • Johns Hopkins Medical Institutions - Baltimore

Michigan

  • University of Michigan Hospitals - Ann Arbor
  • Wayne State - Harper University Hospital - Detroit

Illinois

  • University of Illinois at Chicago - Chicago

Louisiana

  • Tulane University Health Sciences Center - New Orleans

Pennsylvania

  • University of Pennsylvania Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 5,499 participants
Start Date 2003-07
Est. Completion 2028-06

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT00304148

The ClinicalTrials.gov registry entry for NCT00304148 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 5,499 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 257-participant average among 14 other Renal Insufficiency, Chronic trials with a reported enrollment target (2040% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Insufficiency, Chronic appearing as the primary indexed condition, and to 0 interventions.

NCT00304148 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Ohio, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT00304148 about?

NCT00304148 is a clinical study titled "SDCC - Prospective Cohort Study of Chronic Renal Insufficiency". Chronic kidney disease (CKD) is a silent epidemic affecting more than 37 million Americans. The burden of morbidity and mortality associated with CKD derives from its frequent progression to end-stage kidney disease (ESKD) and the disproportionate risk of cardiovascular disease (CVD) and associated ...

What is the current status of trial NCT00304148?

This trial is currently active not recruiting. The enrollment target is 5,499 participants. The study started on 2003-07. Estimated completion is 2028-06.

What conditions does trial NCT00304148 study?

This clinical trial studies the following conditions: Renal Insufficiency, Chronic.

Who is sponsoring clinical trial NCT00304148?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00304148 being conducted?

This trial has 12 study locations across California, Illinois, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Renal Insufficiency, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.